Wet Age Related Macular Degeneration

Wet AMD occurs when abnormal blood vessels grow under the retina and leak causing vision loss.

What is wet macular degeneration?

Wet macular degeneration occurs when abnormal blood vessels (known as choroidal neovascularization) grow under the macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision. It is called wet because of the fluid the leaks from the abnormal blood vessels. Patient with wet macular degeneration usually develop rapid vision loss over the course of weeks or months. Straight lines may look wavy because the macula is no longer smooth. Below is a discussion of various manifestations of wet AMD. Click the button to learn more about the treament of wet AMD

Treatment of Wet AMD

What is a Choroidal Neovascular membrane?

Choroidal neovascular membranes are new blood vessels that grow beneath the retina and disrupt vision. These blood vessels grow in an area called the choroid, the area between the retina and the sclera (the white part of your eye). The choroid supplies oxygen and nutrients to the eye. These blood vessel growths break through the barrier between the choroid and the retina. Although one would think that more blood vessels supplying nutrients to the eye would be good, it is not. The new blood vessels grow out with scarring. Also, they leak more than normal retinal blood vessels. Finally they can bleed and blood is very harmful to the retina. Rarely patient maintain good vision with choroidal neovascular membranes (about 10 or 20 percent). Most people lose central vision rapidly who develop choroidal neovascular membranes unless they are treated.

What is a Disciform Scar?

Untreated, a person with a choroidal neovascular membrane will usually develop a submacular scar like the one in the photo. The scars are white because the are composed mostly of fibroblasts. Subretinal scars cause degeneration of the overlying retina and loss of vision. The scars are circular or disc shaped and therefore are called disciform scars. They cause vision loss because they block the transport of nutrients from the supporting tissue under the retina (the retinal pigment epithelium) which is vital to the survival and function of the retina. Unfortunately, once the retina has been permanently damaged by a submacular scar it cannot be resurrected. Retinal tissue does not regenerate. It cannot be replaced. Research is being pursued all over the world trying to find a way to fix damaged retinas, but nothing, at the moment (January 2015) is close to being effective.

What is Subretinal Fluid?

A hallmark of wet AMD is subretinal fluid. This comes from leaking abnormal blood vessels under the macula. Their is not a firm attachment between the retina and the underlying retinal pigment epithelium. The retina is held in place against the underlying retinal pigment epithelium by a pump in the retinal pigment epithelium. This pump removes naturally occurring fluid in the subretinal space and keeps it dry. The leakage from a choroidal neovascular membrane overwhelms the natural pump in the retinal pigment epithelium and subretinal fluid accumulates. The subretinal fluid distorts the retina causing patients to see things as wavy instead of straight. It also decreases the supply of oxygen and nutrients to the retina and makes the vision blurry. Subretinal fluid is best dectected using optical coherence tomography. The photo shows a dark area under the retina where subretinal fluid has accumulated. The effect (or lack of effect) of treatments for wet macular degeneration is usually evaluated by monitoring the optical coherence tomography scan for subretinal fluid.

What is a Pigment Epithelial Detachment?

Most patients with wet AMD develop a retinal pigment epithelial detachment. The retinal pigment epithelium is a layer of cells under the retina that supports the retina. In the OCT image it is the bright white line closest to the bottom of the picture with RPE on top of it. (there are two lines, the line on the bottom is the RPE, the line on the top is the back of the retina). When fluid or lipid (fatty material) or blood vessels accumulates under the retinal pigment epithelium the retinal pigment epithelium is pushed up. The bump in the retinal pigment epithelium is called a pigment epithelial detachment. These are common in wet AMD. Treatment does not always cause the retinal pigment epithelial detachment to flatten. Vision can be excellent over a retinal pigment epithelial detachment. The distortion of the overlying retina will often cause distortion in the vision. Retinal pigment epithlial detachments do not compromise the ability of the retinal pigment epithelium to nurish the retina. Finally, you can develop a retinal pigment epithelial detachment without wet AMD. These retinal pigment epithelial detachments have lipid (fatty) material in them but no blood vessels. About 90 percent of retinal pigment epithelial detachments are associated with wet AMD and abnormal blood vessel growth.

What is a Polypoidal Choroidal Vasculopathy (PCV)?

Polypoidal choroidal vasculopathy is a subtype of wet AMD that is caused by a mature vascular complex under the retina. It is characterized by a branching vascular network with one or more polyps at the termini of the vessels. The branching vascular network and the polyp(s) are best seen with indocyanine green angiography. There is some evidence the polypoidal choroidal vasculaopathy (PCV) is less response to anti-VEGF injection therapy than other forms of wet AMD. In many cases photodynamic therapy is helpful in treating PCV.

What is a Submacular Hemorrhage (Blood)?

Submacular hemorrhage (blood) is one of the most feared complications of wet AMD. The blood is toxic to the overlying retina and causes immediate severe vision loss. The photo shows blood in a patient whose vision dropped from 20/30 immediately to 20/1600 (no longer able to see even the big letters on the visual acuity chart). Fortunately, submacular hemorrhage is rare and occurs in only about 1 percent of patient with wet AMD. Once there is a submacular hemorrhage, vision almost never returns to what it was before the bleed. Treatment of wet AMD helps reduce the amount of vision loss. Surgery for submacular hemorrhage is controversial and may not be helpful. Visual recovery in someone with a submacular hemorrhage is very very slow. It usually takes about 6 months for the blood to absorb and then another 6-12 months for the overlying retina to heal. Vision usually improves some as the blood absorbs but not much. Most patients recover enough vision to see the big letters on the visual acuity chart but not enough vision to read.

Wet Macular Degeneration NEWS

Below are current articles from a Google News Feed on Wet Macular Degeneration

Global Wet Age-Related Macular Degeneration Markets, 2014-2018 & 2019-2024 - Positive Clinical Trial Results and Increasing Approvals for Pipeline Drugs  PRNewswire

DUBLIN, Aug. 6, 2019 /PRNewswire/ -- The "Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by Route of ...

Senior Living: Macular degeneration and what it means for you  Long Beach Press Telegram

Loss in vision as you age is common among older adults, but not something you should take lightly or ignore. Problems with your vision can be a sign of a new ...

Carl Regillo, MD: Brolucizumab as a Treatment for Macular Degeneration  MD Magazine

Investigators from Wills Eye and Retina Consultants of Austin presented 96-week data from the HAWK and HARRIER trials at ASRS 2019.

Report: Dry AMD requires broad, systems biology approach leveraging big data, multiple disciplines  National Institutes of Health

A large-scale, collaborative, systems biology approach is needed to expedite the discovery of treatments for dry age-related macular degeneration (AMD) – a ...

The huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period  P&T Community

NEW YORK, July 24, 2019 /PRNewswire/ --. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: About this market. Read the full report: ...

Kodiak's AMD med posts promising phase 1b data in 3 eye diseases  FierceBiotech

Eylea and Kodiak's KSI-301 are both anti-VEGF biologics injected into the eye. But KSI-301 has a longer half-life, meaning that patients could go longer between ...

VIDEO: Treat wet AMD patients early to maintain best vision  Healio

CHICAGO — At the American Society of Retina Specialists meeting, David S. Boyer, MD, discusses his presentation comparing anatomical and visual results ...

Expert panel in macular degeneration recommends paradigm shift for future directions  Medical Xpress

A panel of investigators assembled by the National Advisory Eye Council (NAEC) calls for large-scale collaborative research to address dry macular ...

Use of bevacizumab and ranibizumab for wet age-related macular degeneration: Influence of CATT results and introduction of aflibercept  MD Linx

In this retrospective analysis of treatment patterns, researchers ascertained if publication of Comparison of Age-related macular degeneration Treatment Trial ...

Novartis teams with interior designer to help wet AMD patients  PharmaLive

Written by: Administrator | admin@medadnews.com | Dated: Sunday, August 11th, 2019. Novartis is teaming up with celebrity interior designer Nate Berkus to ...

Regenxbio's wet AMD gene therapy shows positive phase 1/2a results  Healio

RGX-314, Regenxbio's gene therapy using NAV vectors for AAV-mediated antibody delivery, has shown positive phase 1/2a results in patients with wet ...

Joshua Mali, MD: Evolution of Care for Macular Degeneration  MD Magazine

Medical Director of the Macular Degeneration Association discusses how the evolution of anti-VEGF treatments has changed the landscape of AMD care and ...

FIDO study shows greater risk for vision loss from undertreatment of wet AMD at 10 years  Healio

CHICAGO — Undertreating patients with neovascular age-related macular degeneration posed a greater risk for vision loss compared with patients treated ...

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD  GlobeNewswire

OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis®. Company to Host Conference Call Today at 9:00 AM AEST 7:00PM ...

Regeneron's Eylea snags prefilled syringe approval as Novartis rival looms  FiercePharma

Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis' challenger brolucizumab is on the horizon. Could a new prefilled syringe ...

Novartis teams with celeb designer Berkus for AMD push—and home tips, too  FiercePharma

TV personality and interior designer Nate Berkus teamed with Novartis for helpful at-home tips for people with age-related macular degeneration, such as ...

Temporal inverted ILM flap technique improves macular hole repair in wet or dry AMD eyes  Healio

CHICAGO — Patients coexisting with dry or wet age-related macular degeneration and macular holes experienced improved vision, anatomic and functional ...

Nate Berkus Designing Homes for Vision Impaired  Healthline

The interior designer and co-host of “Nate & Jeremiah by Design” shares his ideas for home updates that can make spaces safer — without sacrificing style ...

At 2 years, aflibercept injections did not impact CNV conversion rates  Healio

CHICAGO — The 24-month results of the PRO-CON study did not demonstrate a benefit of intravitreal aflibercept injection as prophylaxis against the conversion ...

Scientists make major breakthrough in understanding common eye disease  Science Daily

Scientists have announced a major breakthrough with important implications for sufferers of a common eye disease -- dry Age-Related Macular Degeneration ...

5 Biggest New Drug Approvals Potentially on the Way in 2019  Yahoo Finance

FDA approvals for these drugs could translate to billions of dollars for a few companies.

Physicians' Perspective: Desired Changes Among Retina Specialists  MD Magazine

Carl Regillo, MD, of Wills Eye, and Michael Stewart, of the Mayo Clinic, discuss changes they would like to see in their speciality at ASRS 2019.

Eye on Pharma: FDA Gives Green Light to Aflibercept in Prefilled Syringe  The Center for Biosimilars

Regeneron's aflibercept (Eylea) has been approved by the FDA for a prefilled syringe (PFS) presentation. The 2-mg, single-dose, PFS will offer the greater ease ...

Interesting Sessions to Come at ASRS 2019  MD Magazine

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

A Patient’s Guide to Eye Disease  U.S. News & World Report

Learn about common eye diseases, as well as the symptoms, causes and treatment options, at U.S. News and World Report.

Lawrence Hoffheimer: Legal Hurdles for Retina Specialists  MD Magazine

A former D.C. healthcare attorney and founder of the Macular Degeneration Association discusses legal problems faced by retina specialists when providing ...

Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe  Yahoo Finance

Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.

Opthea to Host Investor Teleconference Australian Stock Exchange:OPT.AX  GlobeNewswire

MELBOURNE, Australia, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company's ...

US, international physicians mostly in agreement over treatment practices  Modern Retina

CHICAGO – In its 20th year, the ASRS Preferences and Trends (PAT) survey is designed to track treatment trends of retinal specialists around the world.

Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval  Pharmacy Times

Officials with the FDA have accepted Novartis' Biologics License Application (BLA) for brolucizumab (RTH258), a humanized single-chain antibody fragment ...

Opthea's Patent Application Covering OPT-302 to be Granted by European Patent Office  GlobeNewswire

MELBOURNE, Australia, July 30, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the European Patent Office (EPO) has ...

Manjot Gill, MD: Baseline Characteristics, Visual Outcomes with Anti-VEGFs  MD Magazine

Manjot Gill, MD, discusses the results of her study which found early diagnosis and treatment of neovascular age-related macular degeneration could help save ...

Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019  GlobeNewswire

CRANBURY, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) today reported business highlights and ...

What Is the Difference Between Wet or Dry Macular Degeneration?  University of Michigan Health System News

Dry macular degeneration occurs when cells of the macula begin to thin and break down. It is characterized by drusen buildup and typically worsens over time.

Global trends show similar patterns worldwide  Modern Retina

The ASRS Global Trends Survey finds differences in some treatment preferences.

Last trial OKed for Eylea to prevent blindness in premature infants  Korea Biomedical Review

The Korean drug regulator has approved a phase-3 clinical trial on Eylea (ingredient: aflibercept), an anti-vascular endothelial growth factor (anti-VEGF) ...

What you need to know about wet macular degeneration  Medical Xpress

Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or ...

Ophthalmology grabs Wall Street's attention  Ophthalmology Times

Editor's Note: Welcome to “Let's Chat,” a blog series featuring contributions from members of the ophthalmic community. These blogs are an opportunity for ...

VIDEO: Oral treatment shows good visual improvement in newly diagnosed wet AMD patients  Healio

FORT LAUDERDALE, Fla. — At the Retina World Congress, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in ...

TRACON Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update  GlobeNewswire

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the ...

7 Tips to Stop Macular Degeneration  Healthline

Macular degeneration is one of the leading causes of blindness in the United States. Here's how to keep your vision safe while enjoying the sun this spring ...

FDA Action Alert: Regeneron, Kala and Vanda  BioSpace

Now that July has come and gone, the U.S. Food and Drug Administration is back to work approving drugs. This week marks three PDUFA target action dates, ...

Alkahest Phase 2a Study AKST4290-202 in Refractory Neovascular AMD meets Primary and Secondary Endpoints  GlobeNewswire

SAN CARLOS, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative ...

Bionic vision system restores sight in AMD trials  The Engineer

Five people suffering from age-related macular degeneration (AMD) have been able to read letters again, following trials of a bionic vision system.

Wet Macular Degeneration Market Opportunities, Leading Players, Survey, Status and Trend Report by 2026  Northwest Arkansas Politics

Wet Macular Degeneration Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods.

12 Revolutionary Advances for Your Eye Health  The Jewish Voice

Eye drops for vision correction, corneal implants, new treatments for macular degeneration and amblyopia among many exciting ophthalmic developments in ...

Preserving independence with innovative interior solutions  KEYE TV CBS Austin

Many seniors may not be aware of a rapidly growing health concern that could impact their independence. It is called age-related Macular Degeneration, and ...

What Is Age-Related Macular Degeneration?  Next Avenue

Age-related macular degeneration (AMD) causes deterioration of the macula, the part of the eye that provides sharp, clear, straight-ahead vision. As many Here ...

Review of Neovascular Age-Related Macular Degeneration Treatment Options  AJMC.com Managed Markets Network

Due to an aging population, visual impairment from neovascular age-related macular degeneration (nAMD) is increasing in the United States. Despite ...

Kodiak Sciences Receives Positive Phase I Data  Contract Pharma

Kodiak Sciences Inc. achieved positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer ...

Implanted drug 'reservoir' safely reduces injections for people with macular degeneration  EurekAlert

In a clinical trial of 220 people with 'wet' age-related macular degeneration, Johns Hopkins Medicine researchers, collaborators from many sites across the ...

RegenxBio and Pfizer Partner on Gene Therapy  PharmaLive

Published: July 31, 2019. By Mark Terry. REGENXBIO, based in Rockville, Maryland, announced it entered a license deal with Pfizer for a gene therapy for ...

Shares soar as Australian AMD drug outperforms Lucentis  Insight News

Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone ...

Age-Related Macular Degeneration: 5 Things to Know  Medscape

A guide to the latest on this chronic disease, from emerging treatments to the risk factors to be on the lookout for.

Age-related Macular Degeneration Market Competitive Landscape Analysis with Forecast by 2025  NewsRegal

The market for AMD is driven by increasing number of AMD patients throughout the world. According to the American Academy of Ophthalmology, in the U.S., ...

University of Southampton researchers develop mouse model of dry AMD  AOP

The mice could help scientists to understand disease progression and test potential new treatments, the University of Southampton reports.

VIDEO: Wet AMD gene therapy trial shows optimistic results  Healio

VANCOUVER, British Columbia —Allen C. Ho, MD, of Wills Eye Hospital discusses phase 1/2 data from a clinical trial of a gene therapy treatment candidate for ...

Opthea unveils favorable results from Phase 2b wet AMD clinical trial  News By ReportsGO

Opthea Limited, a biotechnology and biopharmaceutical company that develops therapies for treatment of eye diseases, has recently announced positive results ...

Eye's vulnerability to macular degeneration revealed  Medical Xpress

Scientists have found significant differences in the shape and biology of the same type of cell taken from different parts of the retina, according to a study in eLife.

Fewer Injections With New Wet Macular Degeneration Therapies  Medscape

New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, ...

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release second-quarter 2019 results on Jul 6, before the opening bell. In the last reported quarter, the ...

Wet Age-Related Macular Degeneration Market to Reach $10.4 Billion by 2024: P&S Intelligence  GlobeNewswire

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- According to the market research report published by P&S Intelligence, global wet age-related macular ...

Vitamins, new treatments offer hope for people with macular degeneration  nwitimes.com

Macular degeneration is the leading cause of vision loss, affecting more than 10 million Americans — more than cataracts and glaucoma combined.

New laser shows promise in treating macular degeneration  WOWT

A breakthrough treatment for macular degeneration is being used on patients in the Rogue Valley. The Medford office using it is believed to be the only one West ...

Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting  BioSpace

Published: Jul 24, 2019. Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented. PALO ALTO, Calif., July 24, 2019 /PRNewswire/ ...

VIDEO: Visual acuity unchanged after macular hole closure in patients with wet AMD  Healio

WAIKOLOA, Hawaii — There was no statistically significant difference in visual acuity results in patients with wet age-related macular degeneration and ...

2 Top Stocks to Buy in August  Yahoo Finance

Summer is rarely kind to biotech stocks. However, this class of equities often starts to regain its footing in the month of August, thanks to a bevy of earnings ...

Trial will be first in US of Nobel-winning stem cell technique  STAT

The NIH is planning the first U.S. clinical trial using induced pluripotent stem cells, to treat age-related macular degeneration.

Seeing clearly: Know your risk for macular degeneration  Baylor College of Medicine News

Baylor College of Medicine's Dr. Christina Weng discusses what you need to know about macular degeneration.

Boosting natural repair could help solve age related macular degeneration  PharmaTimes

Fight for Sight has announced funding for scientists at Queen's University Belfast. - News - PharmaTimes.

Global $10.4 Bn Wet Age-Related Macular Degeneration Market to 2024 - Rising Prevalence of AMD, Lack of a Specific Treatment, and Increasing Aging Population  GlobeNewswire

Dublin, May 15, 2019 (GLOBE NEWSWIRE) -- The "Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by ...

Clinical Catch-up for July 29 – August 2  BioSpace

Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here's a look at some of the clinical ...

Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance  Yahoo Finance

Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

Take steps to prevent vision loss from macular degeneration  Buffalo News

By Judith Whitehead – Contributing Writer Age-related macular degeneration is the leading cause of blindness among older Americans but treatments have ...

7 Healthy Habits to Help Prevent Macular Degeneration  University of Michigan Health System News

AMD affects the eyesight of millions. A Michigan Medicine specialist offers easy ways to help slow or prevent the disease.

Ribomic's wet AMD candidate shows positive phase 1/2a topline results  Healio

A single dose of RBM-007, an oligonucleotide-based aptamer with anti-FGF2 activity, showed positive topline results in a phase 1/2a clinical trial in wet ...

Age-related Macular Degeneration Market: Growth Analysis, Trends and Scope Till 2025  TheWindReports

Age-related macular degeneration is also called macular degeneration, ARMD, or AMD. AMD is a disease of retina that blurs the sharp central vision, which is ...

REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases  PRNewswire

ROCKVILLE, Md. and ZURICH, July 24, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to ...

Dr Boreham’s Crucible: Opthea needs some big licks of dough, but it has set itself up for success  Stockhead

Coming after trial flops from Factor Therapeutics (ASX:FTT), Innate Immunotherapeutics (now Amplia Therapeutics, ASX:ATX) and Bionomics (ASX:BNO), ...

Adverum begins next step of wet AMD gene therapy trial  Healio

Dosing has started in the second cohort of an ongoing phase 1 clinical trial of gene therapy candidate ADVM-022 for the treatment of wet age-related macular ...

Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?  pharmaphorum

Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 with AVEO, and opening up the possibility of ...

VIDEO: Anti-VEGF, ang-2 combination shows potentially longer duration in wet AMD  Healio

FORT LAUDERDALE, Fla. At the Retina World Congress, Carl D. Regillo, MD, director of the retina *service* at Wills Eye Hospital in Philadelphia, discusses ...

Sales lag but Opthea shares jump on trials result  @AuManufacturing

Biopharmaceutical company Opthea (ASX: OPT) ended the week with its shares a record high of $2.91 following news of successful clinical trials, but despite a ...

Experimental drug delivers one-two punch to vision loss: Experiments show new therapy slows blood vessel leakage associated with diabetic macular edema and macular degeneration  Science Daily

In studies with lab-grown human cells and in mice, researchers have found that an experimental drug may be twice as good at fighting vision loss as previously ...

Biologics license application accepted for brolucizumab for wet AMD  Healio

The FDA has accepted a biologics license application for brolucizumab for the treatment of neovascular age-related macular degeneration, Novartis announced ...

FLUID Study Rethinks Treat-and-Extend in Neovascular AMD  Medscape

Study results show that some subretinal fluid can be tolerated after anti-VEGF injections without sacrificing visual outcomes. Dr Charles Wykoff explains why it ...

Human Trials Could Begin for Macular Degeneration Stem Cell Therapy  MD Magazine

FDA trial approval would make this trial the first ever to test a stem cell-based therapy derived from induced pluripotent stem cells for treating any disease.

Regenxbio completes dosing in wet AMD phase 1/2a trial  Healio

Regenxbio has completed dosing in a phase 1/2a clinical trial of its wet age-related macular degeneration treatment candidate, RGX-314, according to a press ...

Novel anti-VEGF for wet AMD meets safety, tolerability endpoint  Healio

WAIKOLOA, Hawaii — Sunitinib, a novel intravitreal anti-VEGF delivered via a biodegradable depot for extended treatment of neovascular age-related macular ...

Two phase 3 trials to investigate faricimab for wet AMD  Healio

Roche and Genentech are initiating two phase 3 global trials to investigate the bispecific molecule faricimab for the treatment of wet age-related macular ...

Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019  Yahoo Finance

Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...

Incredible Growth for Global Ophthalmol Drugs Market by 2025: Industry Analysis, Size, Share, Growth, Trends and Forecast with top Key Players like Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis), Genentech  Indian Columnist

Ophthalmic drugs are extensively used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug ...

Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market  PRNewswire

PALM BEACH, Florida, July 22, 2019 /PRNewswire/ -- According to a report from Grand View Research, the global diabetic foot ulcer treatment market size is ...

A Local Ophthalmologist Uses New Technology to Restore Vision in Patients With Dry Macular Degeneration  Sarasota

In the 1970s TV show, “The Six-Million-Dollar Man,” Steve Austin had, among his many super-human implements, a bionic eye with a tiny telescope to enhance ...

Be aware of age-related macular degeneration  thebellvillestar.com

COLUMBUS — Age-related macular degeneration (AMD), is a leading cause of vision loss for Americans age 50 and older. The eye disease causes damage to.

New laser therapy seeks to halt the progression of age-related vision loss  Medical Xpress

There are 200 million people in the world living with age-related macular degeneration (AMD), and in approximately a fifth of these cases, the disease ...

Aflibercept in the Context of AMD Treatment  MD Magazine

A review highlights aflibercept's efficacy in treatment non-responders and points to a couple promising new AMD therapies in development.

Fresh insights into genes and macular degeneration could open new treatment pathways  FierceBiotech

NIH researchers have pinpointed 6 genomic regions that are closely associated with the development of age-related macular degeneration. (Pixabay).

Implantable Ranibizumab Port for Wet AMD Lasts Up to 15 Months  MD Magazine

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 ...

VIDEO: Notal Vision pursues home-based OCT for wet AMD monitoring  Healio

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Quinton Oswald, CEO of Notal Vision, discusses the company's pursuit of an OCT home ...

» Load more

What about Resources?

Dr. Pautler's Blog
American Academy of Ophthalmology
MedlinePlus
National Institutes of Health
  • ARMD
    NIH's SeniorHealth website covers the topic of Age-Related Macular Degeneration
National Eye Institute
American Foundation for the Blind - Senior Site
  • Macular Degeneration
    Basic information about AMD and low vision; includes a self-test using an Amsler Grid
Journal of the American Medical Association (JAMA)
WebMD
LightHouse International
  • Macular Degeneration
    Provides a general overview of the basics of AMD, and a simulation showing a scene as it might be viewed by a person with AMD
Prevent Blindness America